Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. QIAGEN N.V.
  6. News
  7. Summary
    QGEN   NL0012169213

QIAGEN N.V.

(QGEN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

QIAGEN NV : Receives a Buy rating from Deutsche Bank

10/07/2021 | 07:45am EST

In his latest research note, analyst Falko Friedrichs confirms his positive recommendation. The broker Deutsche Bank is keeping its Buy rating.


ę MarketScreener with dpa-AFX Analyser 2021
All news about QIAGEN N.V.
12/02QIAGEN N.V. : Notification and public disclosure of transactions by persons
EQ
12/02QIAGEN Launches CE-marked Version of QuantiFERON« SARS-CoV-2 to Assess T-cell Response ..
BU
12/01QIAGEN NV : Goldman Sachs reiterates its Neutral rating
MD
11/29Qiagen's Tuberculosis Detection Test Gets FDA Approval for Use on DiaSorin's Liaison XS..
MT
11/29QIAGEN N.V. : Notification and public disclosure of transactions by persons
EQ
11/29QIAGEN and DiaSorin widen access to latent TB testing in the U.S. with FDA approval of ..
BU
11/26Health Care Stocks Slip But Outperform Broader Friday Markets as COVID Worries Re-Emerg..
MT
11/26Qiagen's COVID-19 PCR Tests Remain Accurate in Detecting South African Variant; Shares ..
MT
11/26QIAGEN reaffirms effectiveness of its SARS-CoV-2 PCR tests in light of the new coronavi..
BU
11/26QIAGEN N.V. Reaffirms Effectiveness of SARS-CoV-2 PCR Tests in Light of the New Coronav..
CI
More news
Analyst Recommendations on QIAGEN N.V.
More recommendations
Financials (USD)
Sales 2021 2 196 M - -
Net income 2021 472 M - -
Net Debt 2021 938 M - -
P/E ratio 2021 26,2x
Yield 2021 -
Capitalization 12 432 M 12 432 M -
EV / Sales 2021 6,09x
EV / Sales 2022 6,30x
Nbr of Employees 6 000
Free-Float 97,8%
Chart QIAGEN N.V.
Duration : Period :
QIAGEN N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends QIAGEN N.V.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Last Close Price 54,76 $
Average target price 57,63 $
Spread / Average Target 5,23%
EPS Revisions
Managers and Directors
Thierry Bernard Chief Executive Officer & Managing Director
Roland Sackers Chief Financial Officer & Managing Director
Lawrence A. Rosen Chairman-Supervisory Board
Barthold Piening Senior Vice President & Head-Global Operations
Metin Colpan Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
QIAGEN N.V.1.00%12 159
MODERNA, INC.170.27%114 479
LONZA GROUP AG24.16%58 572
IQVIA HOLDINGS INC.50.86%51 638
SEAGEN INC.-16.39%26 777
CELLTRION, INC.-42.20%23 611